表紙
市場調查報告書

預防疫苗的市場規模(2020年∼2030年)

Global Preventive Vaccines Market, 2020-2030

出版商 ROOTS ANALYSIS 商品編碼 936003
出版日期 內容資訊 英文 248 Pages
商品交期: 最快1-2個工作天內
價格
預防疫苗的市場規模(2020年∼2030年) Global Preventive Vaccines Market, 2020-2030
出版日期: 2020年04月30日內容資訊: 英文 248 Pages
簡介

疫苗是多用途的預防製劑,使得至今病毒性疾病的天花(1980年)和脊髓灰質炎(2015年)可能在全球消滅。根據WHO,全球疫苗接種率達到近85%,防止水痘、白喉、麻疹、肺炎、破傷風、結核等感染疾病為原因發生的近300萬件的死亡。

本報告提供全球預防疫苗市場的相關調查,市場情況及預測,資金、投資,疫苗開發,臨床試驗,各給藥途徑、疫苗類型、疫苗API類型、對象患者族群、地區的市場分析,競爭情形,主要企業的簡介等的資訊。

目錄

第1章 序文

  • 調查範圍
  • 調查手法
  • 章概要

第2章 摘要整理

第3章 簡介

  • 章概要
  • 預防疫苗
    • 疫苗的分類
    • 疫苗製劑的主要零組件
    • 使用了不同表現系統的疫苗的生產
    • 疫苗的給藥途徑
    • 疫苗臨床開發與核准
    • 今後展望

第4章 市場形勢

  • 章概要
  • 預防疫苗
    • 市售疫苗形勢
    • 臨床階段疫苗形勢

第5章 競爭分析

  • 章概要
  • 調查手法
  • 前提條件與主要參數
  • 競爭分析:預防疫苗開發商
    • 以北美為據點的預防疫苗開發商
    • 以歐洲為據點的預防疫苗開發商
    • 以亞太地區為據點的預防疫苗開發商

第6章 企業簡介

  • 章概要
  • Bio Farma
  • Emergent BioSolutions
  • GC Pharma
  • GlaxoSmithKline
  • Janssen
  • Merck
  • Novavax
  • Pfizer
  • Sanofi Pasteur
  • Valneva

第7章 臨床試驗分析

  • 章概要
  • 範圍與調查手法
  • 預防疫苗:臨床試驗分析
    • 試用登記年
    • 登記患者數及實驗登記年
    • 實驗階段
    • 臨床實驗募集情況
    • 研究設計
    • 臨床實驗的焦點地區
    • 預防疫苗類型(基於病原體)
    • 對象疾病適應症
    • 贊助商/合作夥伴的類型
    • 主要的產業企業:登記的臨床實驗數量
    • 被登記的臨床實驗數量:各地區
    • 各登記患者族群:各地區
    • 臨床實驗募集情況:各地區

第8章 對複雜疾病的持續性疫苗開發的配合

  • 章概要
  • 冠狀病毒病(COVID-19)
    • 疾病概要
    • 全球負擔
    • 目前治療形勢
    • 預防疫苗
    • 資金籌措實例
    • 最近的發展
  • 伊波拉病毒病(EVD)
  • HIV/愛滋病
  • 瘧疾
  • 茲卡病毒感染疾病

第9章 與資金籌措投資分析

  • 章概要
  • 資金的種類
  • 預防疫苗:資金籌措和投資分析
    • 資金籌措實例數量
    • 投資額
    • 資金類型
    • 各種類型的疫苗API投資的金額
    • 關注領域
    • 不同的類型的投資者投資額
    • 最積極的參與者:資金籌措實例數量
    • 最積極的投資者:資金籌措實例數量
    • 各地區分析

第10章 市場規模及機會分析

  • 章概要
  • 預測調查手法主要的前提條件
  • 預防疫苗市場整體(2020-2030)
    • 各給藥途徑
    • 各疫苗類型
    • 各疫苗API類型
    • 各對象患者族群
    • 各地區

第11章 適當的例子:疫苗的契約製造

  • 章概要
  • 疫苗受託製造
    • 應對潛在的需求
    • 一般外包營運
    • CMO合作夥伴的選擇
    • 製造服務中外包的優點
    • 關聯的風險與課題
  • 疫苗受託製造
    • 各成立年份分析
    • 各企業規模分析
    • 各運用規模分析
    • 各總公司所在地分析
    • 製造設施的各地點分析
    • 各提供服務形式分析
    • 各使用表現系統分析
    • 製造的各疫苗類型分析
    • 各製造的疫苗類型與各總公司所在地分析

第12章 結論

第13章 經營者的洞察

  • 章概要
  • Alopexx
    • 企業概況
    • 採訪: Daniel R. Vlock,執行長

第14章 附錄1:總計資料

第15章 附錄2:企業、組織的清單

目錄

Overview

Vaccines are versatile preventive formulations that have, so far, enabled the global eradication of smallpox (1980) and polio (2015), which are both debilitating viral diseases. According to the WHO, currently, global vaccination coverage is nearly 85%. This is believed to be responsible for preventing close to three million deaths, which would have otherwise been caused by infectious diseases, such as chickenpox, diphtheria, measles, pneumonia, tetanus, and tuberculosis. In fact, recent immunization records indicate that more than 115 million children are immunized against diphtheria, tetanus and pertussis annually. However, vaccine development, especially against newly identified pathogens, is a challenging and time consuming process. For instance, authorities claim that although there are many initiatives investigating vaccines against the recently identified SARS-CoV-2 coronavirus strain, a viable vaccine is still a year away. Other barriers to vaccine development include lack of pathogen specific information, inadequate immunity (conferred by certain types of vaccines), existence of multiple pathogenic strains, and reversion potential (a phenomenon where a weakened pathogen intended for use as a vaccine, reverts to its infectious phenotype).

Despite the success achieved, so far, through vaccination, it is estimated that over 1.5 million children, under the age of five, die of vaccine-preventable diseases, every year. This is largely attributed to storage (loss of efficacy upon prolonged storage) and logistics-related (cold chain requirement) complexities, which impact adequate distribution and transportation of such medications to remote areas. Given the rate at which the global population is growing, the demand for vaccines is anticipated to increase significantly. In this regard, significant strides have been made in improving existing vaccine formulations, mostly focused on enhancing stability. Recent technical advances, especially in the field of biotechnology, have heralded a new era in immunogen design for vaccine development. Moreover, many developers claim to be working on next generation preventive vaccine candidates, such as recombinant vaccines, viral vector-based vaccines and DNA vaccines, which have been demonstrated to elicit powerful immune responses, resulting in the development of immunologic memory. Further, a variety of adjuvants (substances with the innate potential to augment an immune response) have been discovered and are now available for the development of more versatile vaccine formulations. Several regional government bodies and private investors are actively financing stakeholders in this industry. Given that in the recent past there has been a marked rise in new entrants in this field, we anticipate this market to witness substantial growth in the coming years.

Scope of the Report

The 'Global Preventive Vaccines Market, 2020-2030' report features an extensive study of the current market landscape and future opportunities associated with the preventive vaccine domain. The study also features a detailed analysis of the key drivers and trends related to this evolving segment of the pharmaceutical industry. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape, including information on type of developer (industry, non-industry, industry / non-industry), phase of development (phase I, phase I/II, phase II, phase II/III, phase III and preregistration) of lead candidates, route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others), type of vaccine API (live, attenuated vaccine, recombinant vaccine, conjugate vaccine, inactivated vaccine, DNA vaccine, peptide vaccine, subunit vaccine, mRNA vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule and tablet), dosage (single dose, 2 doses, 3 doses, 4 doses, 5 doses and 6 doses), target disease indication and target patient population (children, adults and seniors).
  • A competitiveness analysis of preventive vaccine developers, taking into consideration supplier strength (based on company size and its experience in this field) and pipeline strength (based on the number of clinical-stage vaccine candidates, highest phase of development, number of compatible routes of administration, number of indications evaluated, number of APIs evaluated and target patient population).
  • Elaborate profiles of the key preventive vaccine developers (shortlisted based on a proprietary criterion) across North America, Europe and Asia Pacific. Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available). In addition to this, the profile includes information on the various clinical-stage vaccine candidates developed by the company. Further, we have provided the recent developments of the company and an informed future outlook.
  • A detailed analysis of more than 1,400 completed, ongoing and planned clinical studies of preventive vaccines, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, trial recruitment status, study design, trial focus area, type of preventive vaccine (based on pathogen), target disease indication(s), type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), enrolled patients population and regional distribution.
  • An overview of the ongoing vaccine development initiatives for complex conditions, such as COVID-19, ebola virus disease, HIV/AIDS, malaria and zika virus infection, including information on disease, its global burden, current treatment landscape and preventive vaccine research landscape. Further, we have provided the information on investments made and recent developments in the domain.
  • An analysis of the investments made in this domain, during the period between 2015 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in developing preventive vaccines.
  • A case study on contract manufacturing landscape for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for preventive vaccines over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] route of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others), [B] type of vaccine (pneumococcal conjugate vaccine, human papilloma virus vaccine, influenza vaccine, rotavirus vaccine, varicella vaccine, DTP-HepB-Hib vaccine, meningococcal group A, C, Y and W-135 vaccine and others), [C] type of vaccine API (live attenuated vaccine, inactivated vaccine, conjugate vaccine, subunit vaccine, toxoid vaccine and others), [D] target patient population (pediatric and adults) and [E] key geographical regions, covering North America (the US, Mexico and Canada), Europe (Spain, the UK, Italy, France, Germany and rest of Europe), Asia Pacific (India, China, Australia and rest of Asia Pacific), and rest of the world. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the preventive vaccines market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to vaccines, as well as their classification based on the type of active ingredient. The chapter also includes an overview of the various expression systems that have been / are being used in the development and production of vaccines. Along with these, later sections highlight a discussion on the various routes of vaccine administration. It also features a brief overview of clinical development and approval processes for vaccines. The chapter ends with a discussion on the challenges and growth drivers that are likely to impact the evolution of the vaccines market in the comping years.

Chapter 4 provides a detailed assessment of the current market landscape of over 200 preventive vaccines that are currently being evaluated in different stages of development. It features a comprehensive analysis of pipeline molecules based on a number of parameters, such as type of developer (industry, non-industry, industry / non-industry), phase of development (phase I, phase I/II, phase II, phase II/III, phase III and preregistration) of lead candidates, route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others), type of vaccine API (live, attenuated vaccine, recombinant vaccine, conjugate vaccine, inactivated vaccine, DNA vaccine, peptide vaccine, subunit vaccine, mRNA vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule and tablet), dosage (single dose, 2 doses, 3 doses, 4 doses, 5 doses and 6 doses), target disease indication and target patient population (children, adults and seniors).

Chapter 5 features an insightful company competitiveness analysis of preventive vaccine developers based in North America, Europe and Asia Pacific. The analysis presents a comparison of the companies within each geography on the basis of supplier strength (based on company size and its experience in this field) and pipeline strength (based on number of clinical-stage vaccine candidates, highest phase of development, number of compatible routes of administration, number of indication evaluated, number of APIs evaluated and target patient population).

Chapter 6 provides elaborate profiles of the key preventive vaccine developers (shortlisted based on a proprietary criterion) across North America, Europe and Asia Pacific. Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available). In addition to this, the profile includes information on the various clinical-stage vaccine candidates developed by the company. Further, we have provided the recent developments of the company and an informed future outlook.

Chapter 7 presents a detailed analysis of more than 1,400 completed, ongoing and planned clinical studies of preventive vaccines, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, trial recruitment status, study design, trial focus area, type of preventive vaccine (based on pathogen), target disease indication(s), type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), enrolled patients population and regional distribution.

Chapter 8 provides an overview of the ongoing vaccine development initiatives for complex conditions, such as COVID-19, ebola virus disease, HIV/AIDS, malaria and zika virus infection, including information on disease, its global burden, current treatment landscape and preventive vaccine research landscape. Further, we have provided the information on investments made and recent developments in the domain.

Chapter 9 presents an analysis of the investments made in this domain, during the period between 2015 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in developing preventive vaccines.

Chapter 10 features a comprehensive market forecast, highlighting the future potential of this market till 2030 based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] route of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others), [B] type of vaccine (pneumococcal conjugate vaccine, human papilloma virus vaccine, influenza vaccine, rotavirus vaccine, varicella vaccine, DTP-HepB-Hib vaccine, meningococcal group A, C, Y and W-135 vaccine and Other), [C] type of API (live attenuated vaccine, inactivated vaccine, conjugate vaccine, subunit vaccine, toxoid vaccine and others), [D] target patient population (pediatric and adults) and [E] key geographical regions, covering North America (the US, Mexico and Canada), Europe (Spain, the UK, Italy, France, Germany and rest of Europe), Asia Pacific (India, China, Australia and rest of Asia Pacific), and rest of the world.

Chapter 11 presents a case study on contract manufacturing landscape for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.

Chapter 12 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 is a collection of interview transcripts of discussions held with key stakeholder(s) in this market.

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Preventive Vaccines
    • 3.2.1. Classification of Vaccines
      • 3.2.1.1. Live, Attenuated Vaccines
      • 3.2.1.2. Inactivated Vaccines
      • 3.2.1.3. Subunit Vaccines
      • 3.2.1.4. Toxoid Vaccines
      • 3.2.1.5. DNA Vaccines
    • 3.2.2. Key Components of a Vaccine Formulation
    • 3.2.3. Production of Vaccines using Different Expression Systems
      • 3.2.3.1. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
      • 3.2.3.2. Mammalian Expression Systems
      • 3.2.3.3. Avian Expression Systems
      • 3.2.3.4. Plant Expression Systems
      • 3.2.3.5. Bacterial Expression Systems
      • 3.2.3.6. Yeast Expression Systems
      • 3.2.3.7. Insect Expression System
    • 3.2.4. Routes of Vaccine Administration
      • 3.2.4.1. Intramuscular Route
      • 3.2.4.2. Subcutaneous Route
      • 3.2.4.3. Oral Route
      • 3.2.4.4. Intranasal Route
      • 3.2.4.5. Intradermal Route
      • 3.2.4.6. Inhalation
    • 3.2.5. Clinical Development and Approval of Vaccines
    • 3.2.6. Future Perspectives

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Preventive Vaccines: Overall Market Landscape
    • 4.2.1. Marketed Vaccines Landscape
    • 4.2.2. Clinical-Stage Vaccines Landscape
      • 4.2.2.1. Analysis by Type of Developer
      • 4.2.2.2. Analysis by Phase of Development
      • 4.2.2.3. Analysis by Route of Administration
      • 4.2.2.4. Analysis by Type of Vaccine API
      • 4.2.2.5. Analysis by Dosage Form
      • 4.2.2.6. Analysis by Dosage
      • 4.2.2.7. Analysis by Target Disease Indication
      • 4.2.2.8. Analysis by Target Patient Population
      • 4.2.2.9. Key Industry Players: Analysis by Number of Vaccines in Clinical Development
      • 4.2.2.10. Key Non-Industry Players: Analysis by Number of Vaccines in Clinical Development

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Methodology
  • 5.3. Assumptions and Key Parameters
  • 5.4. Competitiveness Analysis: Preventive Vaccine Developers
    • 5.4.1. Preventive Vaccine Developers based in North America
    • 5.4.2. Preventive Vaccine Developers based in Europe
    • 5.4.3. Preventive Vaccine Developers based in Asia Pacific

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Bio Farma
    • 6.2.1. Company Overview
    • 6.2.2. Preventive Vaccines Portfolio
    • 6.2.3. Recent Developments and Future Outlook
  • 6.3. Emergent BioSolutions
    • 6.3.1. Company Overview
    • 6.3.2. Preventive Vaccines Portfolio
    • 6.3.3. Recent Developments and Future Outlook
  • 6.4. GC Pharma
    • 6.4.1. Company Overview
    • 6.4.2. Preventive Vaccines Portfolio
    • 6.4.3. Recent Developments and Future Outlook
  • 6.5. GlaxoSmithKline
    • 6.5.1. Company Overview
    • 6.5.2. Preventive Vaccines Portfolio
    • 6.5.3. Recent Developments and Future Outlook
  • 6.6. Janssen
    • 6.6.1. Company Overview
    • 6.6.2. Preventive Vaccines Portfolio
    • 6.6.3. Recent Developments and Future Outlook
  • 6.7. Merck
    • 6.7.1. Company Overview
    • 6.7.2. Preventive Vaccines Portfolio
    • 6.7.3. Recent Developments and Future Outlook
  • 6.8. Novavax
    • 6.8.1. Company Overview
    • 6.8.2. Preventive Vaccines Portfolio
    • 6.8.3. Recent Developments and Future Outlook
  • 6.9. Pfizer
    • 6.9.1. Company Overview
    • 6.9.2. Preventive Vaccines Portfolio
    • 6.9.3. Recent Developments and Future Outlook
  • 6.10. Sanofi Pasteur
    • 6.10.1. Company Overview
    • 6.10.2. Preventive Vaccines Portfolio
    • 6.10.3. Recent Developments and Future Outlook
  • 6.11. Valneva
    • 6.11.1. Company Overview
    • 6.11.2. Preventive Vaccines Portfolio
    • 6.11.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Preventive Vaccines: Clinical Trial Analysis
    • 7.3.1. Analysis by Trial Registration Year
    • 7.3.2. Analysis by Enrolled Patient Population and Trial Registration Year
    • 7.3.3. Analysis by Trial Phase
    • 7.3.4. Analysis by Trial Recruitment Status
    • 7.3.5. Analysis by Study Design
    • 7.3.6. Analysis by Trial Focus Area
    • 7.3.7. Analysis by Type of Preventive Vaccine (based on Pathogen)
    • 7.3.8. Analysis by Target Disease Indication
    • 7.3.9. Analysis by Type of Sponsor / Collaborator
    • 7.3.10. Leading Industry Players: Analysis by Number of Registered Trials
    • 7.3.11. Geographical Analysis by Number of Registered Trials
    • 7.3.12. Geographical Analysis by Enrolled Patient Population
    • 7.3.13. Geographical Analysis by Trial Recruitment Status

8. ONGOING VACCINE DEVELOPMENT INITIATIVES FOR COMPLEX CONDITIONS

  • 8.1. Chapter Overview
  • 8.2. Coronavirus Disease (COVID-19)
    • 8.2.1. Disease Overview
    • 8.2.2. Global Burden of COVID-19
    • 8.2.3. Current Treatment Landscape
    • 8.2.4. Preventive Vaccines for COVID-19
      • 8.2.4.1. Historical Background of COVID-19 Vaccine Research
      • 8.2.4.2. COVID-19 and Affiliated Research Landscape
    • 8.2.5. Funding Instances
    • 8.2.6. Recent Developments
  • 8.3. Ebola Virus Disease (EVD)
    • 8.3.1. Disease Overview
    • 8.3.2. Global Burden of EVD
    • 8.3.3. Current Treatment Landscape
    • 8.3.4. Preventive Vaccines for EVD
      • 8.3.4.1. Historical Background of Ebola Virus Vaccine Research
      • 8.3.4.2. Anti-Ebola Virus Vaccines and Affiliated Research Landscape
    • 8.3.5. Funding Instances
    • 8.3.6. Recent Developments
  • 8.4. HIV/AIDS
    • 8.4.1. Disease Overview
    • 8.4.2. Global Burden of HIV/AIDS
    • 8.4.3. Current Treatment Landscape
    • 8.4.4. Preventive Vaccines for HIV/AIDS
      • 8.4.4.1. Historical Background of HIV/AIDS Vaccine Research
      • 8.4.4.2. Anti-HIV Vaccines and Affiliated Research Landscape
    • 8.4.5. Funding Instances
    • 8.4.6. Recent Developments
  • 8.5. Malaria
    • 8.5.1. Disease Overview
    • 8.5.2. Global Burden of Malaria
    • 8.5.3. Current Treatment Landscape
    • 8.5.4. Preventive Vaccines for Malaria
      • 8.5.4.1. Historical Background of Malaria Vaccine Research
      • 8.5.4.2. Anti-Malaria Vaccines and Affiliated Research Landscape
    • 8.5.5. Funding Instances
    • 8.5.6. Recent Developments
  • 8.6. Zika Virus Infection
    • 8.6.1. Disease Overview
    • 8.6.2. Global Burden of Zika Virus Infection
    • 8.6.3. Current Treatment Landscape
    • 8.6.4. Preventive Vaccines for Zika Virus Infection
      • 8.6.4.1. Historical Background of Zika Virus Vaccine Research
      • 8.6.4.2. Anti-Zika Virus Vaccines and Affiliated Research Landscape
    • 8.6.5. Funding Instances
    • 8.6.6. Recent Developments

9. FUNDING AND INVESTMENT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Types of Funding
  • 9.3. Preventive Vaccines: Funding and Investment Analysis
    • 9.3.1. Analysis by Number of Funding Instances
    • 9.3.2. Analysis by Amount Invested
    • 9.3.3. Analysis by Type of Funding
    • 9.3.4. Analysis by Amount Invested across Different Types of Vaccine API
    • 9.3.5. Analysis by Focus Area
    • 9.3.6. Analysis by Amount Invested by Different Type of Investors
    • 9.3.7. Most Active Players: Analysis by Number of Funding Instances
    • 9.3.8. Most Active Investors: Analysis by Number of Funding Instances
    • 9.3.9. Analysis by Geography
      • 9.3.9.1. Continent-wise Analysis
      • 9.3.9.2. Country-wise Analysis

10. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Forecast Methodology and Key Assumptions
  • 10.3. Overall Preventive Vaccines Market, 2020-2030
    • 10.3.1. Preventive Vaccines Market, 2020-2030: Distribution by Route of Administration
    • 10.3.2. Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine
    • 10.3.3. Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine API
    • 10.3.4. Preventive Vaccines Market, 2020-2030: Distribution by Target Patient Population
    • 10.3.5. Preventive Vaccines Market, 2020-2030: Distribution by Key Geographical Regions
      • 10.3.5.1. Preventive Vaccines Market in North America, 2020-2030
        • 10.3.5.1.1. Preventive Vaccines Market in the US, 2020-2030
        • 10.3.5.1.2. Preventive Vaccines Market in Mexico, 2020-2030
        • 10.3.5.1.2. Preventive Vaccines Market in Canada, 2020-2030
      • 10.3.5.2. Preventive Vaccines Market in Europe, 2020-2030
        • 10.3.5.2.1. Preventive Vaccines Market in Spain, 2020-2030
        • 10.3.5.2.2. Preventive Vaccines Market in the UK, 2020-2030
        • 10.3.5.2.3. Preventive Vaccines Market in Italy, 2020-2030
        • 10.3.5.2.4. Preventive Vaccines Market in France, 2020-2030
        • 10.3.5.2.5. Preventive Vaccines Market in Germany, 2020-2030
        • 10.3.5.2.6. Preventive Vaccines Market in Rest of Europe, 2020-2030
      • 10.3.5.3. Preventive Vaccines Market in Asia Pacific, 2020-2030
        • 10.3.5.3.1. Preventive Vaccines Market in India, 2020-2030
        • 10.3.5.3.2. Preventive Vaccines Market in China, 2020-2030
        • 10.3.5.3.3. Preventive Vaccines Market in Australia, 2020-2030
        • 10.3.5.3.4. Preventive Vaccines Market in Rest of Asia Pacific, 2020-2030
      • 10.3.5.4. Preventive Vaccines Market in Rest of the World, 2020-2030

11. CASE-IN-POINT: CONTRACT MANUFACTURING OF VACCINES

  • 11.1. Chapter Overview
  • 11.2. Vaccine Contract Manufacturing
    • 11.2.1. Addressing an Unmet Need
    • 11.2.2. Commonly Outsourced Operations
    • 11.2.3. Selecting a CMO Partner
    • 11.2.4. Advantages of Outsourcing Manufacturing Services
    • 11.2.5. Associated Risks and Challenges
  • 11.3. Vaccine Contract Manufacturing: Overall Market Landscape
    • 11.3.1. Analysis by Year of Establishment
    • 11.3.2. Analysis by Company Size
    • 11.3.3. Analysis by Scale of Operation
    • 11.3.4. Analysis by Location of Headquarters
    • 11.3.5. Analysis by Location of Manufacturing Facilities
    • 11.3.6. Analysis by Type of Service(s) Offered
    • 11.3.7. Analysis by Expression System Used
    • 11.3.8. Analysis by Type of Vaccine Manufactured
    • 11.3.9. Analysis by Type of Vaccine Manufactured and Location of Headquarters

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

  • 13.1. Chapter Overview
  • 13.2. Alopexx
    • 13.2.1. Company Snapshot
    • 13.2.2. Interview Transcript: Daniel R. Vlock, Chief Executive Officer

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Difference Between Vaccines and Small Molecules
  • Figure 3.2 Classification of Vaccines
  • Figure 3.3 Routes for Vaccine Administration
  • Figure 4.1 Clinical-Stage Preventive Vaccines: Distribution by Type of Developer
  • Figure 4.2 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
  • Figure 4.3 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
  • Figure 4.4 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
  • Figure 4.5 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
  • Figure 4.6 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
  • Figure 4.7 Clinical-Stage Preventive Vaccines: Distribution by Dosage
  • Figure 4.8 Clinical-Stage Preventive Vaccines: Distribution by Target Disease Indication
  • Figure 4.9 Clinical-Stage Preventive Vaccines: Distribution by Target Patient Population
  • Figure 4.10 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
  • Figure 4.11 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
  • Figure 5.1 Company Competitiveness Analysis: Preventive Vaccine Developers based in North America
  • Figure 5.2 Company Competitiveness Analysis: Preventive Vaccine Developers based in Europe
  • Figure 5.3 Company Competitiveness Analysis: Preventive Vaccine Developers based in Asia Pacific
  • Figure 7.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 7.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2020
  • Figure 7.3 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Pre-2010-2020
  • Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 7.5 Clinical Trial Analysis: Distribution by Trial Recruitment Status
  • Figure 7.6 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
  • Figure 7.7 Clinical Trial Analysis: Distribution by Study Design
  • Figure 7.8 Clinical Trial Analysis: Distribution by Trial Focus Area
  • Figure 7.9 Clinical Trial Analysis: Distribution by Type of Preventive Vaccine (based on Pathogen)
  • Figure 7.10 Clinical Trial Analysis: Cumulative Year-wise Trend by Type of Preventive Vaccines
  • Figure 7.11 Clinical Trial Analysis: Distribution by Target Disease Indication
  • Figure 7.12 Clinical Trial Analysis: Distribution by Patient Enrollment and Target Disease Indication
  • Figure 7.13 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 7.14 Leading Industry Players: Distribution by Number of Registered Trials
  • Figure 7.15 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
  • Figure 7.16 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
  • Figure 7.17 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Recruitment Status
  • Figure 8.1 Historical Timeline of COVID-19 Vaccine Development
  • Figure 8.2 Historical Timeline of Anti-Ebola Virus Vaccine Development
  • Figure 8.3 Historical Timeline of Anti-HIV Vaccine Development
  • Figure 8.4 Historical Timeline of Anti-Malaria Vaccine Development
  • Figure 8.5 Historical Timeline of Anti-Zika Virus Vaccine Development
  • Figure 9.1 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2015-Q1 2020
  • Figure 9.2 Funding and Investment Analysis: Cumulative Amount Invested, 2015-Q1 2020 (USD Million)
  • Figure 9.3 Funding and Investment Analysis: Distribution by Type of Funding, 2015-Q1 2020
  • Figure 9.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2015-Q1 2020 (USD Million)
  • Figure 9.5 Funding and Investment Analysis: Distribution of Amount Invested by Type of Vaccine API
  • Figure 9.6 Funding and Investment Analysis: Distribution of Amount Invested and Focus Area
  • Figure 9.7 Funding and Investment Analysis: Distribution of Amount Invested by Different Type of Investors
  • Figure 9.8 Most Active Players: Distribution by Number of Funding Instances
  • Figure 9.9 Most Active Investors: Distribution by Number of Funding Instances
  • Figure 9.10 Funding and Investment Analysis: Regional Distribution by Number of Funding Instances and Amount Raised (USD Million)
  • Figure 9.11 Funding and Investment Analysis: Country-wise Distribution by Total Amount Invested (USD Million)
  • Figure 10.1 Overall Preventive Vaccines Market, 2020-2030 (USD Billion)
  • Figure 10.2 Preventive Vaccines Market, 2020-2030: Distribution by Route of Administration (USD Billion)
  • Figure 10.3 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine (USD Billion)
  • Figure 10.4 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine API (USD Billion)
  • Figure 10.5 Preventive Vaccines Market, 2020-2030: Distribution by Target Patient Population (USD Billion)
  • Figure 10.6 Preventive Vaccines Market, 2020-2030: Distribution by Key Geographical Regions (USD Billion)
  • Figure 10.7 Preventive Vaccines Market in North America, 2020-2030 (USD Billion)
  • Figure 10.8 Preventive Vaccines Market in the US, 2020-2030 (USD Billion)
  • Figure 10.9 Preventive Vaccines Market in Mexico, 2020-2030 (USD Billion)
  • Figure 10.10 Preventive Vaccines Market in Canada, 2020-2030 (USD Billion)
  • Figure 10.11 Preventive Vaccines Market in Europe, 2020-2030 (USD Billion)
  • Figure 10.12 Preventive Vaccines Market in Spain, 2020-2030 (USD Billion)
  • Figure 10.13 Preventive Vaccines Market in the UK, 2020-2030 (USD Billion)
  • Figure 10.14 Preventive Vaccines Market in Italy, 2020-2030 (USD Billion)
  • Figure 10.15 Preventive Vaccines Market in France, 2020-2030 (USD Billion)
  • Figure 10.16 Preventive Vaccines Market in Germany, 2020-2030 (USD Billion)
  • Figure 10.17 Preventive Vaccines Market in Rest of Europe, 2020-2030 (USD Billion)
  • Figure 10.18 Preventive Vaccines Market in Asia Pacific, 2020-2030 (USD Billion)
  • Figure 10.19 Preventive Vaccines Market in India, 2020-2030 (USD Billion)
  • Figure 10.20 Preventive Vaccines Market in China, 2020-2030 (USD Billion)
  • Figure 10.21 Preventive Vaccines Market in Australia, 2020-2030 (USD Billion)
  • Figure 10.22 Preventive Vaccines Market in Rest of Asia Pacific, 2020-2030 (USD Billion)
  • Figure 10.23 Preventive Vaccines Market in Rest of the World, 2020-2030 (USD Billion)
  • Figure 11.1 Type of Third-Party Service Providers in the Pharmaceutical Industry
  • Figure 11.2 Commonly Outsourced Vaccine Development Operations
  • Figure 11.3 Key Factors to Consider while Selecting a CMO Partner
  • Figure 11.4 Risks and Challenges Associated with Contract Manufacturing
  • Figure 11.5 Vaccine CMOs: Distribution by Year of Establishment
  • Figure 11.6 Vaccine CMOs: Distribution by Company Size
  • Figure 11.7 Vaccine CMOs: Distribution by Scale of Operation
  • Figure 11.8 Vaccine CMOs: Distribution by Location of Headquarters (Region and Country-wise)
  • Figure 11.9 Vaccine CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
  • Figure 11.10 Vaccine CMOs: Distribution by Type of Services Offered
  • Figure 11.11 Vaccine CMOs: Distribution by Expression System Used
  • Figure 11.12 Vaccine CMOs: Distribution by Type of Vaccine Manufactured
  • Figure 11.13 Vaccine CMOs: Distribution by Type of Vaccine Manufactured and Location of Headquarters

List Of Tables

  • Table 3.1 Classification of Vaccines
  • Table 3.2 Live, Attenuated Vaccines: Commonly Reported Adverse Events
  • Table 3.3 Inactivated Vaccines: Commonly Reported Adverse Events
  • Table 3.4 Subunit Vaccines: Commonly Reported Adverse Events
  • Table 3.5 Toxoid Vaccines: Commonly Reported Adverse Events
  • Table 3.6 Vaccine Excipients and their Functions
  • Table 3.7 Routes of Administration and Type of Delivery Devices for Vaccine Administration
  • Table 3.8 Common Pediatric Vaccines and their Routes of Administration
  • Table 4.1 List of Marketed Preventive Vaccines
  • Table 4.2 List of Clinical-Stage Preventive Vaccines
  • Table 6.1 Preventive Vaccine Developers: List of Companies Profiled
  • Table 6.2 Bio Farma: Company Overview
  • Table 6.3 Bio Farma: Preventive Vaccine Pipeline
  • Table 6.4 Bio Farma: Recent Developments and Future Outlook
  • Table 6.5 Emergent BioSolutions: Company Overview
  • Table 6.6 Emergent BioSolutions: Preventive Vaccine Pipeline
  • Table 6.7 Emergent BioSolutions: Recent Developments and Future Outlook
  • Table 6.8 GC Pharma: Company Overview
  • Table 6.9 GC Pharma: Preventive Vaccine Pipeline
  • Table 6.10 GC Pharma: Recent Developments and Future Outlook
  • Table 6.11 GlaxoSmithKline: Company Overview
  • Table 6.12 GlaxoSmithKline: Preventive Vaccine Pipeline
  • Table 6.13 GlaxoSmithKline: Recent Developments and Future Outlook
  • Table 6.14 Janssen: Company Overview
  • Table 6.15 Janssen: Preventive Vaccine Pipeline
  • Table 6.16 Janssen: Recent Developments and Future Outlook
  • Table 6.17 Merck: Company Overview
  • Table 6.18 Merck: Preventive Vaccine Pipeline
  • Table 6.19 Merck: Recent Developments and Future Outlook
  • Table 6.20 Novavax: Company Overview
  • Table 6.21 Novavax: Preventive Vaccine Pipeline
  • Table 6.22 Novavax: Recent Developments and Future Outlook
  • Table 6.23 Pfizer: Company Overview
  • Table 6.24 Pfizer: Preventive Vaccine Pipeline
  • Table 6.25 Pfizer: Recent Developments and Future Outlook
  • Table 6.26 Sanofi Pasteur: Company Overview
  • Table 6.27 Sanofi Pasteur: Preventive Vaccine Pipeline
  • Table 6.28 Sanofi Pasteur: Recent Developments and Future Outlook
  • Table 6.29 Valneva: Company Overview
  • Table 6.30 Valneva: Preventive Vaccine Pipeline
  • Table 6.31 Valneva: Recent Developments and Future Outlook
  • Table 8.1 Preventive Vaccines under Investigation for COVID-19
  • Table 8.2 COVID-19 Vaccines: Funding Instances
  • Table 8.3 Ebola Virus Disease: List of Marketed Therapeutics
  • Table 8.4 Preventive Vaccines under Investigation for Ebola Virus Disease
  • Table 8.5 Anti-Ebola Virus Vaccines: Funding Instances
  • Table 8.6 HIV/AIDS: List of Marketed Therapeutics
  • Table 8.7 Preventive Vaccines under Investigation for HIV/AIDS
  • Table 8.8 Anti-HIV Vaccines: Funding Instances
  • Table 8.9 Malaria: List of Marketed Therapeutics
  • Table 8.10 Preventive Vaccines under Investigation for Malaria
  • Table 8.11 Anti-Malaria Vaccines: Funding Instances
  • Table 8.12 Preventive Vaccines under Investigation for Zika Virus Infection
  • Table 8.13 Anti-Zika Virus Vaccines: Funding Instances
  • Table 9.1 Preventive Vaccines: List of Funding and Investments, till Q1 2020
  • Table 11.1 Vaccine Contract Manufacturers: List of Service Providers
  • Table 11.2 Vaccine CMOs: Information on Type of Services Offered
  • Table 11.3 Vaccine CMOs: Information on Scale of Operation
  • Table 11.4 Vaccine CMOs: Information on Expression System Used
  • Table 11.5 Vaccine CMOs: Information on Type of Vaccines Manufactured
  • Table 11.6 List of Ad hoc Vaccine Manufacturers
  • Table 12.1 Preventive Vaccines Market: Summary of the Report
  • Table 14.1 Clinical-Stage Preventive Vaccines: Distribution by Type of Developer
  • Table 14.2 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
  • Table 14.3 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
  • Table 14.4 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
  • Table 14.5 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
  • Table 14.6 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
  • Table 14.7 Clinical-Stage Preventive Vaccines: Distribution by Dosage
  • Table 14.8 Clinical-Stage Preventive Vaccines: Distribution by Target Disease Indication
  • Table 14.9 Clinical-Stage Preventive Vaccines: Distribution by Target Patient Population
  • Table 14.10 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
  • Table 14.11 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
  • Table 14.12 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2020
  • Table 14.13 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Pre-2010-2020
  • Table 14.14 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 14.15 Clinical Trial Analysis: Distribution by Trial Recruitment Status
  • Table 14.16 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
  • Table 14.17 Clinical Trial Analysis: Distribution by Study Design
  • Table 14.18 Clinical Trial Analysis: Distribution by Trial Focus Area
  • Table 14.19 Clinical Trial Analysis: Distribution by Type of Preventive Vaccine (based on Pathogen)
  • Table 14.20 Clinical Trial Analysis: Cumulative Year-wise Trend by Type of Preventive Vaccines
  • Table 14.21 Clinical Trial Analysis: Distribution by Target Disease Indication
  • Table 14.22 Clinical Trial Analysis: Distribution by Patient Enrollment and Target Disease Indication
  • Table 14.23 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 14.24 Leading Industry Players: Distribution by Number of Registered Trials
  • Table 14.25 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2015-Q1 2020
  • Table 14.26 Funding and Investment Analysis: Cumulative Amount Invested, 2015-Q1 2020 (USD Million)
  • Table 14.27 Funding and Investment Analysis: Distribution by Type of Funding, 2015-Q1 2020
  • Table 14.28 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2015-Q1 2020 (USD Million)
  • Table 14.29 Funding and Investment Analysis: Distribution of Amount Invested by Type of Vaccine API
  • Table 14.30 Funding and Investment Analysis: Distribution of Amount Invested by Focus Area
  • Table 14.31 Funding and Investment Analysis: Distribution of Amount Invested by Different Type of Investors
  • Table 14.32 Most Active Players: Distribution by Number of Funding Instances
  • Table 14.33 Most Active Investors: Distribution by Number of Funding Instances
  • Table 14.34 Funding and Investment Analysis: Regional Distribution by Number of Funding Instances and Amount Raised (USD Million)
  • Table 14.35 Funding and Investment Analysis: Country-wise Distribution by Total Amount Invested (USD Million)
  • Table 14.36 Overall Preventive Vaccines Market, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.37 Preventive Vaccines Market, 2020-2030: Distribution by Route of Administration (USD Billion)
  • Table 14.38 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine (USD Billion)
  • Table 14.39 Preventive Vaccines Market, 2020-2030: Distribution by Type of Vaccine API (USD Billion)
  • Table 14.40 Preventive Vaccines Market, 2020-2030: Distribution by Target Patient Population (USD Billion)
  • Table 14.41 Preventive Vaccines Market, 2020-2030: Distribution by Key Geographical Regions (USD Billion)
  • Table 14.42 Preventive Vaccines Market in North America, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.43 Preventive Vaccines Market in the US, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.44 Preventive Vaccines Market in Mexico, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.45 Preventive Vaccines Market in Canada, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.46 Preventive Vaccines Market in Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.47 Preventive Vaccines Market in Spain, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.48 Preventive Vaccines Market in the UK, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.49 Preventive Vaccines Market in Italy, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.50 Preventive Vaccines Market in France, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.51 Preventive Vaccines Market in Germany, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.52 Preventive Vaccines Market in Rest of Europe, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.53 Preventive Vaccines Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.54 Preventive Vaccines Market in India, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.55 Preventive Vaccines Market in China, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.56 Preventive Vaccines Market in Australia, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.57 Preventive Vaccines Market in Rest of Asia Pacific, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.58 Preventive Vaccines Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2020-2030 (USD Billion)
  • Table 14.59 Vaccine CMOs: Distribution by Year of Establishment
  • Table 14.60 Vaccine CMOs: Distribution by Company Size
  • Table 14.61 Vaccine CMOs: Distribution by Scale of Operation
  • Table 14.62 Vaccine CMOs: Distribution by Location of Headquarters (Region and Country-wise)
  • Table 14.63 Vaccine CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
  • Table 14.64 Vaccine CMOs: Distribution by Type of Services Offered
  • Table 14.65 Vaccine CMOs: Distribution by Expression System Used
  • Table 14.66 Vaccine CMOs: Distribution by Type of Vaccines Manufactured
  • Table 14.67 Vaccine CMOs: Region-wise Distribution by Type of Vaccine Manufactured

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. 3P Biopharmaceuticals
  • 2. Abbott Biologicals
  • 3. AbbVie Contract Manufacturing
  • 4. Aberdeen Proving Ground
  • 5. ABL
  • 6. Abu Dhabi Investment Authority
  • 7. Abzena
  • 8. Adimmune
  • 9. Adjuvant Capital
  • 10. Advagene Biopharma
  • 11. Affinivax
  • 12. AJ Biologics
  • 13. AJ Vaccines
  • 14. Ajinomoto Bio-Pharma Services
  • 15. Alexandria Venture Investments
  • 16. Alopexx Vaccine
  • 17. Altimmune
  • 18. AmbioPharm
  • 19. AMRI
  • 20. Anaxago
  • 21. Angels High Tech Investments
  • 22. Anhui Zhifei Longcom Biologic Pharmacy
  • 23. ARCH Venture Partners
  • 24. ArrowMark Partners
  • 25. Astellas Pharma
  • 26. Atlantic Methanol Production Company
  • 27. Auro Vaccines
  • 28. Avid Bioservices
  • 29. AVIR Green Hills Biotechnology
  • 30. aws Gründerfonds
  • 31. Barr Laboratories
  • 32. Batavia Biosciences
  • 33. Bavarian Nordic
  • 34. Baxter BioPharma Solutions
  • 35. Baylor College of Medicine
  • 36. BB Biotech
  • 37. Beijing Center for Disease Control and Prevention
  • 38. Beijing Institute of Biological Products
  • 39. Beijing Minhai Biotechnology
  • 40. Beijing Zhifei Lvzhu Biopharmaceutical
  • 41. Bharat Biotech
  • 42. Bharat Serums and Vaccine
  • 43. Bill & Melinda Gates Foundation
  • 44. Bilthoven Biologicals
  • 45. BINEX
  • 46. Bio Elpida
  • 47. Bio Farma
  • 48. BioCell
  • 49. BioConnections
  • 50. Biofabri
  • 51. Biological E.
  • 52. Bio-Manguinhos
  • 53. BioMARC
  • 54. Biomay
  • 55. Biomedical Advanced Research and Development Authority
  • 56. BioMedPartners
  • 57. BiondVax Pharmaceuticals
  • 58. BioReliance
  • 59. BioTechLogic
  • 60. BioTechnique
  • 61. BlueWillow Biologics
  • 62. Boehringer Ingelheim BioXcellence
  • 63. Boehringer Ingelheim Venture Fund
  • 64. Boryung Pharmaceutical
  • 65. Brammer Bio
  • 66. Bryllan
  • 67. Bul Bio-National Center of Infectious and Parasitic Diseases
  • 68. Burrard Pharmaceuticals
  • 69. Cadila Healthcare
  • 70. CanSino Biologics
  • 71. CARBOGEN AMCIS
  • 72. CARB-X
  • 73. Catalent
  • 74. Center for Genetic Engineering and Biotechnology
  • 75. Century Pharmaceuticals
  • 76. CEPI
  • 77. Cerberus Capital Management
  • 78. CEVEC Pharmaceuticals
  • 79. Charles River Laboratories
  • 80. Chengdu Institute of Biological Products
  • 81. Chiron Behring Vaccines
  • 82. Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences
  • 83. CJ HealthCare
  • 84. Cobra Biologics
  • 85. Codagenix
  • 86. Consort Medical
  • 87. CRG
  • 88. CSL
  • 89. CureVac
  • 90. Curevo
  • 91. Cytovance Biologics
  • 92. Dalton Pharma Services
  • 93. Danish Government
  • 94. Danish Innovation Foundation
  • 95. Dartmouth-Hitchcock Medical Center
  • 96. Deerfield Management
  • 97. Department of the Army
  • 98. Division of AIDS
  • 99. Duke Human Vaccine Institute
  • 100. Dynavax Technologies
  • 101. EDBI
  • 102. EirGenix
  • 103. Emergent BioSolutions
  • 104. Emergent Product Development Gaithersburg
  • 105. Emergex Vaccines
  • 106. Ethiopian Government
  • 107. EuBiologics
  • 108. Euclidean Capital
  • 109. Eurofins Amatsigroup
  • 110. Eurogentec
  • 111. EDCTP
  • 112. European Investment Bank
  • 113. European Union
  • 114. Eveliqure Biotechnologies
  • 115. Farallon Capital
  • 116. Federal State Budgetary Scientific Institution
  • 117. FF DSF VI
  • 118. Fidelity Investments
  • 119. Fiocruz
  • 120. FluGen
  • 121. Forbion
  • 122. Fort Detrick
  • 123. Fortune Capital
  • 124. FUJIFILM Diosynth Biotechnologies
  • 125. FundRx
  • 126. Future Industry Investment Fund
  • 127. Gamaleya Research Institute of Epidemiology and Microbiology
  • 128. GC Cell
  • 129. GC Pharma
  • 130. GeneMatrix
  • 131. GeneOne Life Science
  • 132. GenIbet Biopharmaceuticals
  • 133. Georgia Institute of Technology
  • 134. Gilead
  • 135. GlaxoSmithKline
  • 136. Global Health Investment Fund
  • 137. Goldstone Investment
  • 138. Gopher Asset Management
  • 139. Government of the Republic of Equatorial Guinea
  • 140. Government of Norway
  • 141. GPO-MBP
  • 142. GreenPak Biotech
  • 143. GreenSignal Bio Pharma
  • 144. GTP Technology
  • 145. GV
  • 146. Hadean Ventures
  • 147. Haffkine Bio-Pharmaceutical
  • 148. HALIX
  • 149. Hawaii Biotech
  • 150. HBM Partners
  • 151. Health Biotech
  • 152. HealthCap
  • 153. Hillhouse Capital
  • 154. Hong Kong Institute of Biotechnology
  • 155. HOOKIPA Pharma
  • 156. Hualan Biological Bacterin
  • 157. Icahn School of Medicine at Mount Sinai
  • 158. IDT Biologika
  • 159. ILiAD Biotechnologies
  • 160. Il-Yang Pharmaceutical
  • 161. Immunobiological Technology Institute (BioManguinhos)
  • 162. Imperial College London
  • 163. Indian Immunologicals
  • 164. Infectious Disease Research Institute
  • 165. Innovate UK
  • 166. Inovio Pharmaceuticals
  • 167. Institut Pasteur de Dakar
  • 168. Institute for Biomedical Science
  • 169. Institute of Vaccines and Medical Biologicals
  • 170. Instituto Nacional de Saúde
  • 171. Intas
  • 172. Integrity Bio
  • 173. International AIDS Vaccine Initiative
  • 174. International Centre for Diarrhoeal Disease Research, Bangladesh
  • 175. International Vaccine Institute
  • 176. Invus
  • 177. Israel Innovation Authority
  • 178. Israel Investment Center
  • 179. Jack Ma Foundation
  • 180. Janssen
  • 181. Japan Bank for International Cooperation
  • 182. Japan BCG Laboratory
  • 183. JEMS Venture Capital
  • 184. Jiangsu Provincial Center for Disease Control and Prevention
  • 185. JN-International Medical
  • 186. Johnson & Johnson Innovation
  • 187. Joint Program Executive Office for Chemical and Biological Defense
  • 188. JSR
  • 189. Jubilant HollisterStier
  • 190. Julius Baer
  • 191. Kemwell Biopharma
  • 192. King Abdullah International Medical Research Center
  • 193. Knox
  • 194. Korea Investment Partners
  • 195. LF Investment
  • 196. LG Chem
  • 197. Lilly Asia Ventures
  • 198. LimmaTech Biologics
  • 199. Line Moon Ventures
  • 200. Liontrust
  • 201. Lonza
  • 202. LuinaBio
  • 203. Mahidol University
  • 204. Marathon Oil Corporation
  • 205. Massachusetts General Hospital
  • 206. MassBiologics
  • 207. MCM Vaccine
  • 208. Ministry of Health of the Russian Federation
  • 209. Medicago
  • 210. Medical Countermeasure Systems'Joint Vaccine Acquisition Program
  • 211. Medigen Vaccine Biologics
  • 212. MedImmune
  • 213. Meissa Vaccines
  • 214. Merck
  • 215. Meridian Life Science
  • 216. MIKROGEN
  • 217. MinervaX
  • 218. Ministry of Economic Affairs
  • 219. Ministry of Foreign Affairs (Netherlands)
  • 220. Moderna
  • 221. Morningside Ventures
  • 222. MRC/UVRI Uganda Research Unit on AIDS
  • 223. MSD Wellcome Trust Hilleman Laboratories
  • 224. Mymetics
  • 225. Natick Contracting Division
  • 226. National Authority for Technological Innovation
  • 227. National Institute of Allergy and Infectious Diseases
  • 228. National Institutes of Health
  • 229. National Vaccine & Serum Institute
  • 230. Network-1 Technologies
  • 231. Nitto Avecia Pharma Services
  • 232. Noble Energy
  • 233. North Coast Technology Investors
  • 234. Noshaq
  • 235. Nova Immunotherapeutics
  • 236. Novartis
  • 237. Novartis Venture Fund
  • 238. Novasep
  • 239. Novavax
  • 240. Novo Holdings
  • 241. Novo Seeds
  • 242. NPO Petrovax Pharm
  • 243. Omnes Capital
  • 244. OPKO Health
  • 245. OrbiMed
  • 246. Organon Teknika
  • 247. Osivax
  • 248. Oxford Sciences Innovation
  • 249. Panacea Biotec
  • 250. PATH
  • 251. Perceptive Advisors
  • 252. Pfizer
  • 253. Pfizer CentreOne
  • 254. Pictet
  • 255. Pierre Fabre
  • 256. Piramal Pharma Solutions
  • 257. PnuVax
  • 258. Polymun Scientific
  • 259. Porton Biopharma
  • 260. Premas Biotech
  • 261. ProBioGen
  • 262. Profectus BioSciences
  • 263. Protein Sciences
  • 264. PX'Therapeutics
  • 265. Qiming Venture Partners
  • 266. Redmile Group
  • 267. Redmont Capital
  • 268. Reliance Life Sciences
  • 269. Research Foundation for Microbial Diseases, Osaka University
  • 270. Richter-Helm Biologics
  • 271. Rommelag CMO
  • 272. RTW Investments
  • 273. Russian Academy of Sciences
  • 274. Sabin Vaccine Institute
  • 275. Samsara BioCapital
  • 276. Sanaria
  • 277. Sanofi Pasteur
  • 278. Scandinavian Biopharma
  • 279. Scripps Research Institute
  • 280. SDS Capital Partners
  • 281. Seedlings Life Science Ventures
  • 282. SEEK
  • 283. Seqirus
  • 284. Sequoia
  • 285. Sequoia China
  • 286. Serum Institute of India
  • 287. Shanghai Bovax Biotechnology
  • 288. Shantha Biotechnics
  • 289. Sinovac Biotech
  • 290. Sirona Capital
  • 291. SK Bioscience
  • 292. Sofinnova Partners
  • 293. State of Wisconsin Investment Board
  • 294. Sunstone Capital
  • 295. Sunstone Life Science Ventures
  • 296. Swissfillon
  • 297. Syngene
  • 298. Takeda
  • 299. Takeda Ventures
  • 300. Teva Pharmaceuticals
  • 301. Texas Biomedical Research Institute
  • 302. The Peter Doherty Institute for Infection and Immunity
  • 303. The Wistar Institute
  • 304. Themis Bioscience
  • 305. Thermo Fisher Scientific
  • 306. Topspin Partners
  • 307. Truffle Capital
  • 308. UK Government
  • 309. UK Research and Innovation
  • 310. Univercells
  • 311. University Health Network
  • 312. University Medical Center Hamburg-Eppendorf
  • 313. University of Amsterdam
  • 314. University of Antwerp
  • 315. University of California
  • 316. University of Georgia
  • 317. University of Maryland
  • 318. University of Michigan
  • 319. University of Minnesota
  • 320. University of Oxford
  • 321. University of Washington
  • 322. US Agency for International Development
  • 323. US Army Contracting Command
  • 324. US Army Medical Research and Materiel Command
  • 325. US Centers for Disease Control and Prevention
  • 326. US Defense Advanced Research Projects Agency
  • 327. US Defense Threat Reduction Agency
  • 328. US Department of Agriculture
  • 329. US Department of Defense
  • 330. Vaccitech
  • 331. Valneva
  • 332. Vaxart
  • 333. Vaxine
  • 334. VaxNewMo
  • 335. Vaxxilon
  • 336. VBI Vaccines
  • 337. Ventech
  • 338. Venture Investors
  • 339. Vetter Pharma
  • 340. VGXI
  • 341. Vibalogics
  • 342. Vickers Venture Partners
  • 343. Viking Global Investors
  • 344. Wacker Biotech
  • 345. Waisman Biomanufacturing
  • 346. Wallace Pharmaceuticals
  • 347. Wellington Partners Life Sciences
  • 348. Wisconsin Alumni Research Foundation
  • 349. WuXi Biologics
  • 350. Wuxi Griffin
  • 351. Wyeth Pharmaceuticals
  • 352. Xiamen University
  • 353. X-Vax Technology